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Abstract:  A  series  of  novel  2-(4-substitutedbenzylthio)-5-amino-6-(benzo[d]thiazol-2-yl)-7-(4-
chlorophenyl)pyrido[2,3-d]pyrimidin-4(3H)-one derivatives were synthesized and evaluated for their antibacterial 
and antifungal activity. All the derivatives were efficiently synthesized in four steps. The structure of the newly 
synthesized  compounds  was  elucidated  by  their  IR, 
1H-NMR, 
13C  NMR,  LCMS  mass  spectra and  elemental 
analysis.  
Keywords:  2-(4-substitutedbenzylthio)-5-amino-6-(benzo[d]thiazol-2-yl)-7-(4-chlorophenyl)pyrido[2,3-d]-
pyrimidin-4(3H)-one; antibacterial; antifungal. 
_______________________________________________________________________ 
 
1. Introduction 
Developing new antimicrobial agents (antibacterial and antifungal) continues to attract attention 
and is an area of rigorous research. Although a large number of antibiotics and chemotherapeutics are 
available  for  medical  use,  the  antimicrobial  resistance  created  a  substantial  need  of  new  class  of 
antimicrobial agents in the last decades.
1–3 Pyrido[2,3-d]pyrimidines and its derivatives have distinct 
status as pharmaceutical agents. They have been found to have high therapeutic value  as herbicide 
antidotes
4,  diuretic
5,  anti-inflammatory
6  and  insecticidal  agents
7,  anticancer  and  antiviral
8-12, 
anticonvulsive
13, growth regulator
14, antileishmaniasis
15, and anticancer agents
16,17 Recently, based upon 
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a  diverse  range  of  biological  properties  and  the  potential  for  folate  antagonists
18,19  to  elicit  highly 
species-specific responses as antitumour
20,21, in addition pyrido[2,3-d]pyrimidines derivatives revealing 
promising antimicrobial activities.
22–27 In continued quest of new antimicrobial agents, we designed and 
synthesized  novel  pyrido[2,3-d]pyrimidines  having   benzothiazole  group. Structures of the products 
were  characterized  by  IR, 
1H-NMR, 
13C  NMR,  LCMS  mass  spectrometry,  and  elemental  analysis. 
Results of biological activities indicate that some compounds possess potential antimicrobial activity. 
 
2. Results and Discussion 
Our synthesis was started from 2-(benzo[d]thiazol-2-yl)acetonitrile (1). The condensation of 1 
with  2-cyanoacetic  acid  in  Ac2O  gave  compound  2.  Knoevenagel  condensation  of  2  with  4-
chlorobenzaldehyde gave compound 3. 6-amino-2-thioxo-2,3-dihydropyrimidin-4(1H)-one was reacted 
with compound 3 in the air atmosphere gave pyrido[2,3-d]pyrimidin-4(1H)-one 4. Compound 4 was 
alkylated with benzyl halides to give 5a-j.  
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Reagents and conditions: (i) Acetic anhydride, reflux 20 min; (ii) EtOH, piperidine, reflux 4 h; 
             (iii) EtOH, piperidine, reflux 6 h; (iv) DMF, K2CO3, 1h. 
 
Scheme 1. Synthetic pathway for compound 5 a-j. 
3. Pharmacological assay       
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3.1. Antibacterial assay 
A standard inoculum (1-2 X 10
7 c.f.u/cm
3 0.5 McFarland standards) was introduced on to the 
surface of sterile agar plates, and a sterile glass spreader was used for even distribution of the inoculum. 
The discs measuring 6.25 mm in diameter were prepared from Whatman no.1 filter paper and sterilized 
by dry heat at 140 
oC for 1 h. The sterile disc previously soaked in a known concentration of the test 
compounds were placed in nutrient agar medium. Solvent and growth controls were kept. The plates 
were inverted and incubated for 24 h at 37 
oC. The inhibition zones were measured and compared with 
the controls. Minimum inhibitory concentration (MIC) was determined by broth dilution technique. The 
nutrient  broth,  which  contained  logarithmic serially  two  fold diluted  amount  of  test  compound and 
controls were inoculated with approximately  
5 X 10
5 c.f.u of actively dividing bacteria cells. The cultures were incubated for 24 h at 37 
oC and the 
growth was monitored visually and spectrophotometrically. The lowest concentration (highest dilution) 
required to arrest the growth of bacteria was regarded as minimum inhibitory concentrations (MIC). 
Ciprofloxacin  was  used  as  a  standard  drug.  The  diameter  of  the  zone  of  inhibition  and  minimum 
inhibitory concentration values are given in Table 1. 
The  newly  synthesized  compounds  were  screened  for  their  antibacterial  activity  against 
Escherichia  coli,  Staphylococcus  aureus,  Pseudomonas  aeruginosa,  Streptococcus  pyogenes  and 
Klebsiella pneumoniae (recultured) bacterial strains by disc diffusion method.
28,29 The investigation of 
antibacterial screening data revealed that all the tested compounds showed moderate to good bacterial 
inhibition. The compounds 5a, 5b, 5e, 5f, 5i and 5j showed very good activity against all the bacterial 
strains. 
 
3.2. Antifungal assay 
Sabouraud’s agar media was prepared by dissolving 1 g peptone, 4 g D-glucose, and 2 g agar in 
100  cm
3  distilled  water,  and  adjusting  pH  to  5.7  using  buffer.  Normal  saline  was  used  to  make  a 
suspension of spore of fungal strain for lawning. A loop full of particular fungal strains was transferred 
to 3 cm
3 saline to get a suspension of corresponding species. 20 cm
3 of agar media was poured in to 
each Petri dish. Excess of suspension was decanted and the plates were dried by placing in a incubator 
at 37 
oC for 1 h. Using an agar punch, wells were made and each well was labeled. A control was also 
prepared in triplicate and maintained at 37 
oC for 3-4 d. The inhibition zones in diameter were measured 
and compared with the controls. The Nutrient Broth, which contained logarithmic serially two fold 
diluted amount of test compound and controls was inoculated with approximately 1.6 X 10
4-6 X 10
4 
c.f.u cm
-3. The cultures were incubated for 48 h at 35 
oC and the growth was monitored. The lowest 
concentration  (highest  dilution)  required  to  arrest  the  growth  of  fungus  was  regarded  as  minimum 
inhibitory concentrations (MIC). Amphotericin B was used as the standard drug. The diameter of zone 
of inhibition and minimum inhibitory concentration values are given in Table 2. 
Newly  prepared  compounds  were  screened  for  their  antifungal  activity  against  Aspergillus 
flavus,  Aspergillus  fumigatus,  Candida  albicans,  Penicillium  marneffei  and  Trichophyton 
mentagrophytes (recultured) in DMSO by serial plate dilution method
30,31. The antifungal screening data 
showed moderate to good activity. Compounds 5a, 5c, 5f, 5i and 5j emerged as very good active against 
all the fungal strains. 
 
 
 
 
 
Table 1: Antibacterial activity of thiazolotriazinoes (5a-j). Rao.et al., Org. Commun. (2011) 4:2 33-41 
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Compound 
no 
Staphylococcus 
aureus 
Eschrichia 
coli 
Pseudomonas 
aeruginosa 
Klebsiella 
pneumoniae 
Streptococcus 
pyogenes 
5a  20 (6.25)  25 (6.25)  29 (6.25)  18 (6.25)  23 (6.25) 
5b  23 (6.25)  28 (6.25)  30 (6.25)  18 (6.25)  21 (6.25) 
5c  10 (12.5)  --  --  17 (6.25)  11 (6.25) 
5d  8 (25)  23 (6.25)  9 (25)  --  8 (12.5) 
5e  22 (6.25)  27 (6.25)  32 (6.25)  20 (6.25)  24 (6.25) 
5f  21 (6.25)  29 (6.25)  32 (6.25)  20 (6.25)  23 (6.25) 
5g  10 (12.5)  15 (25)  --  --  17 (12.5) 
5h  12 (12.5)  --  21 (6.25)  --  8 (25) 
5i  21 (6.25)  24 (6.25)  29 (6.25)  19 (6.25)  23 (6.25) 
5j  21 (6.25)  26 (6.25)  32 (6.25)  21 (6.25)  24 (6.25) 
Standard
a  24 (6.25)  30 (6.25)  33 (6.25)  23 (6.25)  25 (6.25) 
-- Indicates bacteria is resistant to the compounds at > 100 µg/ml, MIC values are given in brackets. MIC (µg/ml) 
= minimum inhibitory concentration, ie. Lowest concentration to completely inhibit bacterial growth. Zone of 
inhibition in mm. 
a Ciprofloxacin was used as standard. 
 
 
Table 2: Antifungal activity of thiazolotriazinoes (5a-j). 
 
Compound 
no 
Aspergillus 
fumigatus 
Aspergillus 
flavus 
Trichophyton 
mentagrophytes 
Penicillium 
marneffei 
Candida 
albicans 
5a  22 (6.25)  22 (6.25)  25 (6.25)  22 (6.25)  20 (6.25) 
5b  8 (25)  --  12 (12.5)  --  17 (6.25) 
5c  22 (6.25)  20 (6.25)  22 (6.25)  25 (6.25)  17 (6.25) 
5d  15 (6.25)  --  7 (25)  21 (6.25)  18 (6.25) 
5e  5 (25)  18 (6.25)  --  12 (12.5)  17 (6.25) 
5f  24 (6.25)  21 (6.25)  21 (6.25)  23 (6.25)  18 (6.25) 
5g  11 (12.5)  12 (25)  --  --  14 (12.5) 
5h  9 (25)  --  12 (12.5)  9 (25)  10 (12.5) 
5i  22 (6.25)  19 (6.25)  20 (6.25)  23 (6.25)  19 (6.25) 
5j  21 (6.25)  26 (6.25)  32 (6.25)  21 (6.25)  24 (6.25) 
Standard
b  25 (6.25)  21 (6.25)  23 (6.25)  25 (6.25)  19 (6.25) 
-- Indicates fungus is resistant to the compounds at >100 mg/ml, MIC values are given in brackets. MIC (mg/ml) = 
minimum inhibitory concentration, ie. Lowest concentration to completely inhibit fungal growth. Zone of 
Inhibition in mm. 
b Amphotericin was used as standard. 
 
4. Conclusion 
The investigation of antibacterial screening data reveals that among the 10 compounds screened, five 
compounds showed good bacterial and six compounds showed fungal inhibition almost equivalent to 
that of standard. 
 
5. Experimental       
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All reagents and solvents were purchased and used without further purification. Melting points 
were determined on a Fisher–Johns melting point apparatus and are uncorrected. Crude products were 
purified by column chromatography on silica gel of 60–120 mesh. IR spectra were obtained on a Perkin 
Elmer BX serried FT-IR 5000 spectrometer using KBr pellet. NMR spectra were recorded on a Varian 
300 MHz spectrometer for 
1H NMR. The 
13C NMR spectra were recorded on JEOL. The chemical shifts 
were reported as ppm down field using TMS as an internal standard. Mass spectra were recorded on a 
MASPEC low resolution mass spectrometer operating at 70 eV. 
 
5.1.  2-(Benzo[d]thiazol-2-yl)-3-oxopentanedinitrile (2) 
To a solution of cyanoacetic acid (0.01 mol) and acetic anhydride (15 mL) that was heated on 
water bath for 5 min, 2-(benzo[d]thiazol-2-yl)acetonitrile (1) (0.01 mol) was added and the reaction 
mixture was refluxed for 20 min at 85-95 
oC. After the mixture was cooled the formed solid was filtered 
off, dried and recrystallized from ethanol to afford 1.69 g (70%) of 2; mp 275 
oC; brown crystals; IR 
(KBr) (υ, cm
-1): 2185, 2199 (2CN), 1700 (CO). 
1H NMR (DMSO-d6): δ, 4.52 (s, 2H, CH2), 5.10 (s, 1H, 
CH), 6.67-7.50 (m, 4H, Ar-H). LCMS: (m/z, %): 241 (M)
+. Anal. Calcd. for C12H7N3OS: C, 59.74; H, 
2.92; N, 17.42. Found: C, 59.92; H, 2.97; N, 17.53. 
 
5.2.  2-(Benzo[d]thiazol-2-yl)-3-(4-chlorophenyl)-acrylonitrile  (3):  
To a solution of 2 (0.01 mol) and p-chlorobenzaldehyde (0.01 mol) in ethanol (20 mL), was 
added a few drops of piperidine and the reaction mixture was refluxed for 4 h, then left to cool (Scheme 
1). The precipitate that formed was filtered off, washed with ethanol and purified by recrystallized from 
ethanol to afford 2.11 g (71%) of 3; mp > 300 
oC; yellow powder; IR (KBr) (υ, cm
-1): 3119 (NH), 2188 
(CN). 
1H NMR (DMSO-d6): δ, 7.32-8.12 (m, arom. + vinylic H). LCMS: (m/z, %): 298 (M+1)
+. Anal. 
Calcd. for C16H9ClN2S: C, 64.75; H, 3.06; N, 9.44. Found: C, 64.84; H, 3.17; N, 9.51. 
 
5.3.    5-Amino-6-(benzo[d]thiazol-2-yl)-7-(4-chlorophenyl)-2-thioxo-2,3-dihydropyrido-[2,3-
d]pyrimidin-4(1H)-one  (4):  
To a mixture of 3 (0.01 mol), 6-aminothiouracil (0.01 mol) in ethanol (15 mL), a catalytic 
amount of piperidine was added. The reaction mixture was refluxed for 6 h, allowed to cool and poured 
into  ice  cold  water.  The  precipitated  solid  obtained  was  filtered  off,  dried  and  recrystallized  from 
ethanol to furnish 2.72 g (62%) of 4; mp 230 
oC; pale yellow powder; IR (KBr) (υ, cm
-1): 3402, 3389 
(NH2), 3141 (NH), 1698 (CO), 1221 (C=S). 
1H NMR (DMSO-d6): δ, 6.22 (s, 2H, NH2), 7.32-8.49 (m, 
8H,  Ar-H),  13.51  (s,  1H,  NH),  13.59  (s,  1H,  NH).  LCMS:  (m/z,  %):  438  (M)
+.  Anal.  Calcd.  for 
C20H12ClN5OS2: C, 54.84; H, 2.76; N, 15.99. Found: C, 54.94; H, 2.82; N, 16.04. 
 
5.4. General Procedure of 2-(4-substituted benzylthio)-5-amino-6-(benzo[d]thiazol-2-yl)-7-
(4-chlorophenyl)pyrido[2,3-d]-pyrimidin-4(3H)-ones (5a-j):  
An  ice  cold  solution  of  cyclic  compound  of  5-amino-6-(benzo[d]thiazol-2-yl)-7-(4-
chlorophenyl)-2-thioxo-2,3-dihydropyrido-[2,3-d]pyrimidin-4(1H)-one  (4)  (1  mol)  in  DMF  (4  vol), 
potassium carbonate (1.5 mol) and substituted benzyl halides (1.3 mol) was taken in a 1 liter round 
bottomed flask equipped with magnetic stirrer and stirred for 1 hour. The residual portion was poured 
on to crushed ice, neutralized with dilute acid and the product obtained 2-(4-substituted benzylthio)-5-
amino-6-(benzo[d]thiazol-2-yl)-7-(4-chlorophenyl)pyrido[2,3-d]-pyrimidin-4(3H)-one derivatives (5a-j) 
was collected by filtration.  Rao.et al., Org. Commun. (2011) 4:2 33-41 
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5-Amino-6-(benzo[d]thiazol-2-yl)-2-(benzylthio)-7-(4-chlorophenyl)pyrido[2,3-d]- 
pyrimidin-4(3H)-one (5a): Pale yellow solid; Yield 69%; m.p. 196-198 
oC; IR (KBr): υ 3402-3389 
(NH2), 3141 (NH), 1698 (CO) cm
-1; 
1H NMR (300 MHz, DMSO-d6): δ 4.10 (s, 2H, CH2), 6.23 (s, 2H, 
NH2), 7.32-8.49 (m, 13H, Ar-H), 13.58 (s, 1H, NH); 
13C NMR (DMSO-d6): δ 168.23, 164.52, 161.72, 
158.36,  157.44,  155.86,  154.21,  141.29,  138.67,  137.12,  136.84,  133.46,  133.10,  132.53,  131.64, 
130.92, 128.29, 127.83, 124.52, 124.19, 120.89, 110.92, 40.10. LCMS: (m/z) 528 (M+1).
+ Anal. Calcd. 
for C27H18ClN5OS2: C, 61.41; H, 3.44; N, 13.26. Found: C, 61.55; H, 3.53; N, 13.39. 
 
2-(4-Bromobenzylthio)-5-amino-6-(benzo[d]thiazol-2-yl)-7-(4-chlorophenyl)pyrido[2,3-d]-
pyrimidin-4(3H)-one (5b): Yellow solid; Yield 63%; m.p. 214-216 
oC; IR (KBr): υ 3410-3383 (NH2), 
3155 (NH), 1680 (CO) cm
-1; 
1H NMR (300 MHz, DMSO-d6): δ 4.15 (s, 2H, CH2), 6.25 (s, 2H, NH2), 
7.10-8.49 (m, 12H, Ar-H), 13.55 (s, 1H, NH); 
13C NMR (DMSO-d6): δ 168.45, 164.59, 161.70, 158.43, 
157.48,  155.81,  153.97,  140.87,  138.77,  137.25,  136.93,  135.41,  134.13,  133.55,  133.12,  128.32, 
127.88,  125.24,  124.50,  124.23,  121.10,  110.98,  40.57.  LCMS  (m/z)  608  (M+2)
+.
  Anal.  Calcd.  for 
C27H17BrClN5OS2: C, 53.43; H, 2.82; N, 11.54. Found: C, 54.14; H, 2.95; N, 11.65. 
 
2-(4-Ethylbenzylthio)-5-amino-6-(benzo[d]thiazol-2-yl)-7-(4-chlorophenyl)pyrido[2,3-d]-
pyrimidin-4(3H)-one (5c): Yellow solid; Yield 75%; m.p. 175-176 
oC; IR (KBr): υ 3410-3370 (NH2), 
3155 (NH), 1698 (CO) cm
-1; 
1H NMR (300 MHz, DMSO-d6): δ 1.4 (t, 3H, CH3, J = 6.2), 2.35 (q, 2H, 
CH2 J = 7.4), 4.15 (s, 2H, SCH2), 6.30 (s, 2H, NH2), 7.20-8.49 (m, 12H, Ar-H), 13.58 (s, 1H, NH); 
LCMS (m/z) 556 (M+1)
+.
 Anal. Calcd. for C29H22ClN5OS2: C, 62.64; H, 3.99; N, 12.59. Found: C, 
63.12; H, 4.21; N, 12.73. 
 
2-(4-Methylbenzylthio)-5-amino-6-(benzo[d]thiazol-2-yl)-7-(4-chlorophenyl)pyrido[2,3-d]-
pyrimidin-4(3H)-one (5d): Pale yellow solid; Yield 65%; m.p. 224-225 
oC; IR (KBr): υ 3410-3365 
(NH2), 3165 (NH), 1710 (CO) cm
-1; 
1H NMR (300 MHz, DMSO-d6): δ 2.15 (s, 3H, CH3), 4.10 (s, 2H, 
CH2), 6.30 (s, 2H, NH2), 7.10-8.45 (m, 12H, Ar-H), 13.51 (s, 1H, NH); LCMS (m/z) 542 (M+1)
+.
 Anal. 
Calcd. for C28H20ClN5OS2: C, 62.04; H, 3.72; N, 12.92. Found: C, 62.43; H, 3.96; N, 13.04. 
 
2-(4-Methoxybenzylthio)-5-amino-6-(benzo[d]thiazol-2-yl)-7-(4-lorophenyl)pyrido[2,3-  d]-
pyrimidin-4(3H)-one (5e): Yellow solid; Yield 76%; m.p. 171-173 
oC; IR (KBr): υ 3400-3380 (NH2), 
3165 (NH), 1710 (CO) cm
-1; 
1H NMR (300 MHz, DMSO-d6): δ 3.06 (s, 3H, OCH3), 4.21 (s, 2H, CH2), 
6.30 (s, 2H, NH2), 7.20-8.45 (m, 12H, Ar-H), 13.51 (s, 1H, NH); LCMS (m/z) 558 (M+1)
+.
 Anal. Calcd. 
for C28H20ClN5O2S2: C, 60.26; H, 3.61; N, 12.55. Found: C, 60.62; H, 3.88; N, 12.83. 
 
2-(4-(Dimethylamino)benzylthio)-5-amino-6-(benzo[d]thiazol-2-yl)-7-(4-chlorophenyl) 
-pyrido[2,3-d]-pyrimidin-4(3H)-one (5f): Yellow solid; Yield 82%; m.p. 210-212 
oC; IR (KBr): υ 
3400-3365  (NH2),  3160  (NH),  1710  (CO)  cm
-1; 
1H  NMR  (300  MHz,  DMSO-d6):  δ  3.02  (s,  6H,  
N(CH3)2), 4.20 (s, 2H, CH2), 6.25 (s, 2H, NH2), 7.10-8.49 (m, 12H, Ar-H), 13.51 (s, 1H, NH); LCMS 
(m/z) 571 (M+1)
+.
 Anal. Calcd. for C29H23ClN6OS2: C, 60.99; H, 4.06; N, 14.71. Found: C, 61.49; H, 
4..61; N, 14.93. 
 
2-(4-Chlorobenzylthio)-5-amino-6-(benzo[d]thiazol-2-yl)-7-(4-chlorophenyl)pyrido[2,3-d]-
pyrimidin-4(3H)-one (5g): Yellow solid; Yield 80%; m.p. 252-254 
oC; IR (KBr): υ 3410-3345 (NH2), 
3160 (NH), 1720 (CO) cm
-1; 
1H NMR (300 MHz, DMSO-d6): 4.20 (s, 2H, CH2), 6.30 (s, 2H, NH2), 7.0-
8.50 (m, 12H, Ar-H), 13.51 (s, 1H, NH); LCMS (m/z) 562 (M+1)
+.
 Anal. Calcd. for C27H17Cl2N5OS2: C, 
57.65; H, 3.05; N, 12.45. Found: C, 57.94; H, 3.54; N, 12.82. 
 
2-(4-Isopropylbenzylthio)-5-amino-6-(benzo[d]thiazol-2-yl)-7-(4-chlorophenyl)pyrido       
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-[2,3-d]-pyrimidin-4(3H)-one (5h): Yellow solid; Yield 78%; m.p. 185-187 
oC; IR (KBr): υ 3410-3330 
(NH2), 3190 (NH), 1720 (CO) cm
-1; 
1H NMR (300 MHz, DMSO-d6): δ 1.20 (d, 6H, (CH3)2), 2.70-2.87 
(m, 1H, CH), 4.10 (s, 2H, CH2), 6.20 (s, 2H, NH2), 7.20-8.50 (m, 12H, Ar-H), 13.58 (s, 1H, NH); 
13C 
NMR (DMSO-d6): δ 168.17, 164.48, 161.69, 158.27, 157.40, 155.81, 154.18, 148.32, 139.34, 138.62, 
137.08, 136.79, 133.50, 132.96, 132.12, 130.71, 128.32, 127.81, 124.47, 124.17, 120.88, 110.88, 40.12, 
38.74, 28.63. LCMS (m/z) 570 (M+1)
+.
 Anal. Calcd. for C30H24ClN5OS2: C, 63.20; H, 4.24; N, 12.28. 
Found: C, 63.69; H, 4.63; N, 12.55. 
 
2-(4-Tert-butyl-benzylthio)-5-amino-6-(benzo[d]thiazol-2-yl)-7-(4-chlorophenyl)pyrido 
[2,3-d]-pyrimidin-4(3H)-one (5i): Pale yellow solid; Yield 71%; m.p. 202-204 
oC; IR (KBr): υ 3410-
3320 (NH2), 3190 (NH), 1720 (CO) cm
-1; 
1H NMR (300 MHz, DMSO-d6): δ 1.35 (s, 9H, (CH3)3), 4.10 
(s,  2H,  CH2),  6.25  (s,  2H,  NH2),  7.20-8.50  (m, 12H,  Ar-H),  13.51  (s,  1H,  NH);  LCMS  (m/z)  584 
(M+1)
+.
 Anal. Calcd. for C31H26ClN5OS2: C, 63.74; H, 4.49; N, 11.99. Found: C, 64.06; H, 4.87; N, 
12.21. 
2-((1,2,3,4-Tetrahydronaphthalen-5-yl)methylthio)-5-amino-6-(benzo[d]thiazol-2-yl)-7-(4-
chlorophenyl)pyrido-[2,3-d]-pyrimidin-4(3H)-one (5j): Pale yellow solid; Yield 69%; m.p. 221-223 
oC; IR (KBr): υ 3400-3310 (NH2), 3155 (NH), 1710 (CO) cm
-1; 
1H NMR (300 MHz, DMSO-d6): δ 1.45-
2.65 (m, 7H), 4.10 (s, 2H, CH2), 6.20 (s, 2H, NH2), 7.20-8.50 (m, 11H, Ar-H), 13.51 (s, 1H, NH); 
LCMS (m/z) 582 (M+1)
+.
 Anal. Calcd. for C31H24ClN5OS2: C, 63.96; H, 4.16; N, 12.09. Found: C, 
64.23; H, 4.42; N, 12.38. 
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